Stelexis Therapeutics

Stelexis Therapeutics is a privately held company based in New York, New York. Founded in 2017, the company employs 10 people and generates an annual revenue of $2.5 million. Stelexis Therapeutics focuses on the discovery and development of novel cancer therapeutics. Their proprietary platform identifies, isolates, and studies stem and progenitor cells that contribute to tumor formation. This platform serves as a target identification engine and drug discovery tool, aiming to address unmet needs in various cancer indications. The company's mission is to transform the cancer therapeutics paradigm and patient care. Their research focuses on understanding the role of early-stage cancer cells in tumor development and utilizing this knowledge to develop innovative treatments. For more information, visit stelexis.com.